Alnylam Pharmaceuticals (ALNY) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) in the last few weeks:

• 11/28/2024 – Alnylam Pharmaceuticals was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/19/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at William Blair.
• 11/18/2024 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
• 11/18/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 11/12/2024 – Alnylam Pharmaceuticals was downgraded by analysts at Wolfe Research from a “peer perform” rating to an “underperform” rating.
• 11/4/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Scotiabank from $305.00 to $310.00. They now have a “sector outperform” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Barclays PLC from $295.00 to $329.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Raymond James from $275.00 to $298.00. They now have an “outperform” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “buy” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
• 10/21/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at TD Cowen from $282.00 to $371.00. They now have a “buy” rating on the stock.
• 10/18/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 10/16/2024 – Alnylam Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $305.00 price target on the stock.
• 10/14/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Bank of America Co. from $307.00 to $314.00. They now have a “buy” rating on the stock.
• 10/11/2024 – Alnylam Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $220.00 price target on the stock.
• 10/11/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
• 10/10/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
• 10/10/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.

Alnylam Pharmaceuticals Stock Up 1.1 %

Alnylam Pharmaceuticals stock traded up $2.88 during trading on Wednesday, reaching $254.72. The stock had a trading volume of 422,337 shares, compared to its average volume of 870,035. The stock has a market cap of $32.85 billion, a PE ratio of -97.22 and a beta of 0.32. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The business has a 50 day moving average price of $270.31 and a 200 day moving average price of $243.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 earnings per share. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Cetera Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $238,000. GAMMA Investing LLC lifted its position in Alnylam Pharmaceuticals by 97.2% during the second quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 205 shares during the period. Fulton Bank N.A. purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $247,000. CWM LLC lifted its position in Alnylam Pharmaceuticals by 102.8% during the second quarter. CWM LLC now owns 3,492 shares of the biopharmaceutical company’s stock worth $849,000 after buying an additional 1,770 shares during the period. Finally, Symmetry Partners LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $278,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.